Navigation Links
The "DNDi Project of the Year": The Development of Fexinidazole to Treat "Sleeping Sickness"
Date:6/27/2008

NERVIANO, Italy, June 27 /PRNewswire/ --

- Accelera Recognised as Key Partner in the Development of a New Therapy

The development of fexinidazole for the treatment of African trypanosomiasis, commonly known as "sleeping sickness", by DNDi (Drugs for Neglected Diseases initiative), along with Accelera, a business unit of Nerviano Medical Sciences (NMS), is to be honoured as one of DNDi's Success Stories of the Year. The award will be conferred today in New York, at the prestigious headquarters of the New York Academy of Sciences, during the first annual Stakeholders' Meeting of DNDi. Accelera is recognised as DNDi's key partner in the non-clinical development of fexinidazole.

"We are proud to receive this recognition," comments Dr. Marco Brughera - Vice President of Accelera - "and happy to be able to contribute to improving the health of populations living in the poorest countries. We were delighted to be selected from among several international Contract Research Organisations (CROs) to be DNDi's partner of choice for characterizing the preclinical profile of fexinidazole"

"The preclinical work to support the profiling of fexinidazole started at Accelera more than one year ago," Dr Brughera points out "and included a series of in vitro and preliminary activities followed by a full package of tolerability and safety studies as requested by Regulatory Authorities. The results obtained have allowed DNDi to proceed to the next stage of fexinidazole's development, with a quick registration being a primary goal."

Accelera carries out preclinical development activities for molecules targeting various different therapeutic classes, including collaborations aimed at defining therapeutic solutions for other "neglected diseases," such as malaria, visceral leishmaniasis, African trypanosomiasis, and Chagas' disease.

"Our pride in this recognition is twofold: on the one hand there is the satisfaction of being an active collaborator within such international projects, and on the other the knowledge that we have been able to make our contribution to a humanitarian initiative like that of DNDi," continues Giampiero Duglio, Managing Director of NMS.

About Accelera (http://www.accelera.info)

Accelera, BU of Nerviano Medical Sciences, is a premium tier Contract Research Organization (CRO), working and collaborating with pharmaceutical and biotechnology companies around the world. Committed to offering the highest levels of service throughout drug discovery and development, our expertise can make a difference, right from the start.

About Nerviano Medical Sciences - NMS (http://www.nervianoms.com)

NMS is a research based company dedicated to the discovery and development of breakthrough new chemical entities (NCEs) for the treatment of cancer. NMS was incorporated in May 2004 as a spin-off from Pfizer and is wholly owned by the Rome-based Congregazione dei Figli dell'Immacolata Concezione (CFIC).

For further information please contact:

Accelera (Nerviano Medical Sciences)

Maria D'Acquino, mob +39-335-1863052

maria.d'acquino@nervianoms.com


'/>"/>
SOURCE Nerviano Medical Sciences (NMS): Accelera
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. QI projects may -- or may not -- improve patient safety and outcomes
2. MU researchers to collaborate on $20 million project
3. Fry Construction Selected for High-Profile Medical Imaging Project
4. Jacobs Receives Contract for New Hospital Project in Belgium
5. IVCC launches groundbreaking insecticide projects with Bayer and Syngenta
6. Global Health Project targets reducing AIDS among Indias adolescents
7. Uncontrolled Blood Pressure Highest Among Hispanics, Prompting New Hypertension Project in San Antonio
8. New Business Development of Multi-Hospital Project!
9. ARIZONA METH PROJECT Unveils Arizonas Anti-Meth Youth Pledge and Kicks Off Phase Two of Public Awareness Campaign
10. Meth Project Advertisements Selected for National Prevention Campaign
11. Pillow, PAs Great American Sleep Better(TM)Project Reports Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... 12, 2016 , ... Miami Dental Specialists is excited to bring patients the ... Beginning in January, Miami Dental Specialists will offer the non-metal implants as a safe, ... to be chosen by the dental implant manufacturer, Straumann, to bring this cutting-edge technology ...
(Date:2/12/2016)... ... February 12, 2016 , ... J Thomas & ... continuing it’s commitment to act as Agents of Change in the community, announces ... area homeless families to fulfill immediate needs and help them move into permanent ...
(Date:2/12/2016)... ... February 12, 2016 , ... Nearly every health website ... health. These articles generally list between five and 15 foods that should be ... every one of these lists and believes that nutritious eye healthy foods are ...
(Date:2/12/2016)... ... February 12, 2016 , ... Homeowners now have a next ... North America’s leading brand of building products, has improved upon its industry-best array ... mobile version of the ColorView® Exterior Style and Color Selector. Created expressly for ...
(Date:2/12/2016)... Colo. (PRWEB) , ... February 12, 2016 , ... A ... the past 35 years. A president has access to health and wellness resources most ... the free world, no single individual has a schedule as frenetic as the U.S. ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... , Feb. 11, 2016 The primary goal ... future adoption patterns on the usage of liquid biopsy. ... following: - Timeframe of liquid biopsy adoption ... cfDNA and Evs—by organization type - Sample inflow to ... blood, saliva, stool, serum, and so on. - Correlation ...
(Date:2/11/2016)... PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its ... also filed its Quarterly Report on Form 10-Q for the ... Exchange Commission today. --> --> ... --> Net sales for the three months ... $5.4 million from $2.8 million for the three months ended ...
(Date:2/11/2016)... 2016  Kindred Biosciences, Inc. (NASDAQ: KIN ), ... lives of pets, today announced the submission to FDA ... Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive ... Zimeta for the control of pyrexia (fever) in horses ... --> --> The Chemistry, Manufacturing, and ...
Breaking Medicine Technology: